Viridian Therapeutics Inc [VRDN] stock prices are down -2.76% to $23.26 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRDN shares have gain 2.24% over the last week, with a monthly amount glided 65.08%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Viridian Therapeutics Inc [NASDAQ: VRDN] stock has seen the most recent analyst activity on September 11, 2024, when Needham reiterated its Buy rating and also boosted its price target to $38 from $30. Previously, Wolfe Research started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $29. On June 06, 2024, Goldman initiated with a Buy rating and assigned a price target of $23 on the stock. Ladenburg Thalmann downgraded its rating to a Neutral. B. Riley Securities downgraded its rating to a Neutral and reduced its price target to $20 on May 09, 2024. In a note dated June 14, 2023, BTIG Research initiated an Buy rating and provided a target price of $46 on this stock.
The stock price of Viridian Therapeutics Inc [VRDN] has been fluctuating between $10.93 and $24.75 over the past year. Currently, Wall Street analysts expect the stock to reach $37.83 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $23.26 at the most recent close of the market. An investor can expect a potential return of 62.64% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Gross Profit Margin for this corporation currently stands at -2.58% with Operating Profit Margin at -870.78%, Pretax Profit Margin comes in at -791.86%, and Net Profit Margin reading is -791.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.5 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.73 points at the first support level, and at 22.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.14, and for the 2nd resistance point, it is at 25.03.
Ratios To Look Out For
It’s worth pointing out that Viridian Therapeutics Inc [NASDAQ:VRDN]’s Current Ratio is 15.82. In addition, the Quick Ratio stands at 15.82 and the Cash Ratio stands at 2.93. Considering the valuation of this stock, the price to sales ratio is 6124.60, the price to book ratio is 4.51.
Transactions by insiders
Recent insider trading involved Beetham Thomas W., Chief Operating Officer, that happened on Sep 27 ’24 when 5000.0 shares were purchased. President and CEO, Mahoney Stephen F. completed a deal on Sep 27 ’24 to buy 21400.0 shares. Meanwhile, Director Fairmount Funds Management LLC bought 1.6 million shares on Sep 13 ’24.
